Managed Service Contract for Viral Molecular Pathology Testing

The Molecular Pathology Diagnostic Service (MPDS) is looking to advertise provision of a managed service (MSC) encompassing EGFR, BRAF, KRAS and NRAS testing over a range of cancer types. The trust will be looking at solutions to provide equipment and reagents for the molecular testing of clinically relevant mutations in EGFR, BRAF, KRAS and NRAS from DNA extracted from formalin fixed paraffin embedded tissue and circulating tumour DNA from plasma.

There is an expectation that the FFPE DNA used in the tests above may be required in subsequent tests not covered by this managed service therefore provision for DNA extraction from FFPE material is not included within the scope of this MSC and supplied solutions for the assays required must be agnostic of DNA extraction methods used. Extraction and testing of circulating tumour DNA from plasma for use in EGFR mutation testing will be included in the scope of the MSC.